We analyzed the TGFβ1 content in the tumor tissues (Fig. 5c–e) and found that the amount of TGFβ1 decreased in the DETA-Dex group and the DETA-Dex/PD-1 inhibitor combination group compared with the group treated with only the PD-1 inhibitor. The gene discussed is TGFB1; the disease is neoplasm.